PD-1 KO mice treated with isotype controls exhibited significantly reduced tumor growth rates compared to their wild-type (WT) counterparts, confirming that abrogation of PD-1 itself was sufficient for anti-tumor immunity (Figure 7F). Here, PDCD1 is linked to neoplasm.